确定全科就诊儿童特应性皮炎的严重程度：一种简单快速的方法。
Determining the severity of atopic dermatitis in children presenting in general practice: an easy and fast method.
作者信息
Willemsen Marjolein G, van Valburg Rosalinda W C, Dirven-Meijer Pauline C, Oranje Arnold P, van der Wouden Johannes C, Moed Heleen
机构信息
Department of General Practice, Erasmus MC-University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.
出版信息
Dermatol Res Pract. 2009;2009:357046. doi: 10.1155/2009/357046. Epub 2009 Nov 18.
Abstract
Assessment of the severity of atopic dermatitis (AD) is necessary to evaluate the disease process. This study evaluates and validates the TIS in children with AD presenting in general practice. Independent investigators determined the severity of AD using the TIS and the objective SCORAD. The interobserver agreement for the TIS and SCORAD was calculated, as was the correlation between TIS and SCORAD. The mean time to assess the TIS was less than one minute. A moderate-to-good agreement between the observers was found for the TIS (kappa = 0.604 or 0.464), or SCORAD (kappa = 0.695 or 0.700). There was an excellent correlation between TIS and SCORAD (r(s) = 0.755-0.839). In conclusion, the TIS is an easy and fast method to score AD. Because of the moderate to good interobserver agreement and the high correlation with the SCORAD, we recommend the TIS to determine the severity of AD in general practice.
摘要
评估特应性皮炎（AD）的严重程度对于评估疾病进程很有必要。本研究对在全科医疗中就诊的AD患儿的总体疾病严重程度（TIS）进行评估并验证。独立研究人员使用TIS和客观SCORAD来确定AD的严重程度。计算了TIS和SCORAD的观察者间一致性，以及TIS和SCORAD之间的相关性。评估TIS的平均时间不到一分钟。观察者之间对TIS（kappa = 0.604或0.464）或SCORAD（kappa = 0.695或0.700）的一致性为中等至良好。TIS和SCORAD之间存在极好的相关性（r(s) = 0.755 - 0.839）。总之，TIS是一种简单快速的AD评分方法。由于观察者间一致性中等至良好，且与SCORAD高度相关，我们建议在全科医疗中使用TIS来确定AD的严重程度。
相似文献
1
Determining the severity of atopic dermatitis in children presenting in general practice: an easy and fast method.确定全科就诊儿童特应性皮炎的严重程度：一种简单快速的方法。
Dermatol Res Pract. 2009;2009:357046. doi: 10.1155/2009/357046. Epub 2009 Nov 18.
2
Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies.特应性皮炎严重程度评分：三项严重程度评分作为日常实践的粗略系统以及研究的预筛查工具。
Acta Derm Venereol. 1999 Sep;79(5):356-9. doi: 10.1080/000155599750010256.
3
Severity scoring of atopic dermatitis: a comparison of three scoring systems.特应性皮炎的严重程度评分：三种评分系统的比较。
Allergy. 1997 Sep;52(9):944-9. doi: 10.1111/j.1398-9995.1997.tb01255.x.
4
Correlation between Objective SCORAD and Three-Item Severity Score used by physicians and Objective PO-SCORAD used by parents/patients in children with atopic dermatitis.特应性皮炎患儿中医生使用的客观SCORAD与三项严重程度评分以及家长/患者使用的客观PO-SCORAD之间的相关性。
Dermatology. 2015;230(2):105-12. doi: 10.1159/000367689. Epub 2015 Jan 31.
5
Clinical characteristics and estimation severity of the atopic dermatitis in children.儿童特应性皮炎的临床特征及严重程度评估
Med Arh. 2010;64(3):178-82.
6
Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score.特应性皮炎评分解读的实际问题：SCORAD指数、客观SCORAD及三项严重程度评分
Br J Dermatol. 2007 Oct;157(4):645-8. doi: 10.1111/j.1365-2133.2007.08112.x. Epub 2007 Aug 21.
7
Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis.特应性皮炎青少年和成人患者的湿疹面积和严重程度指数（EASI）、改良 EASI、特应性皮炎评分（SCORAD）、客观 SCORAD、特应性皮炎严重程度指数和体表面积严重程度分层。
Br J Dermatol. 2017 Nov;177(5):1316-1321. doi: 10.1111/bjd.15641. Epub 2017 Oct 1.
8
Validation of five patient-reported outcomes for atopic dermatitis severity in adults.五项成人特应性皮炎严重程度患者报告结局的验证
Br J Dermatol. 2020 Jan;182(1):104-111. doi: 10.1111/bjd.18002. Epub 2019 Jul 24.
9
Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe.患者自评 SCORAD（PO-SCORAD）：在欧洲验证的特应性皮炎新的自我评估量表。
Allergy. 2011 Aug;66(8):1114-21. doi: 10.1111/j.1398-9995.2011.02577.x. Epub 2011 Mar 18.
10
Automatic SCOring of Atopic Dermatitis Using Deep Learning: A Pilot Study.使用深度学习对特应性皮炎进行自动评分：一项初步研究。
JID Innov. 2022 Feb 11;2(3):100107. doi: 10.1016/j.xjidi.2022.100107. eCollection 2022 May.
引用本文的文献
1
Nonprescription Treatment Options.非处方治疗选择。
Adv Exp Med Biol. 2024;1447:151-167. doi: 10.1007/978-3-031-54513-9_14.
2
Staphylococcal diversity in atopic dermatitis from an individual to a global scale.从个体到全球范围的特应性皮炎中葡萄球菌的多样性。
Cell Host Microbe. 2023 Apr 12;31(4):578-592.e6. doi: 10.1016/j.chom.2023.03.010.
3
Effect of Vitamin D on the Treatment of Atopic Dermatitis With Consideration of Heterogeneities: Meta-Analysis of Randomized Controlled Trials.考虑异质性的维生素D对特应性皮炎治疗的影响：随机对照试验的荟萃分析
Allergy Asthma Immunol Res. 2023 Mar;15(2):262-270. doi: 10.4168/aair.2023.15.2.262.
4
Clinical and Humanistic Burden of Atopic Dermatitis in Europe: Analyses of the National Health and Wellness Survey.欧洲特应性皮炎的临床和人文负担：国民健康与幸福调查分析
Dermatol Ther (Heidelb). 2022 Apr;12(4):949-969. doi: 10.1007/s13555-022-00700-6. Epub 2022 Mar 28.
5
Strategies for using topical corticosteroids in children and adults with eczema.湿疹患儿和成人中局部皮质类固醇的使用策略。
Cochrane Database Syst Rev. 2022 Mar 11;3(3):CD013356. doi: 10.1002/14651858.CD013356.pub2.
6
The effectiveness of antibacterial therapeutic clothing based on silver or chitosan as compared with non-antibacterial therapeutic clothing in patients with moderate to severe atopic dermatitis (ABC trial): study protocol for a pragmatic randomized controlled trial.基于银或壳聚糖的抗菌治疗性衣物与非抗菌治疗性衣物在中重度特应性皮炎患者中的疗效比较（ABC 试验）：一项实用随机对照试验的研究方案。
Trials. 2021 Dec 11;22(1):902. doi: 10.1186/s13063-021-05836-y.
7
Differences in Psychometric Properties of Clinician- and Patient-Reported Outcome Measures for Atopic Dermatitis by Race and Skin Tone: A Systematic Review.按种族和肤色划分的特应性皮炎患者报告结局评估工具的心理测量学特性的差异：系统评价。
J Invest Dermatol. 2022 Feb;142(2):364-381. doi: 10.1016/j.jid.2021.06.033. Epub 2021 Aug 2.
8
Quality of life in infants with atopic dermatitis and their families.特应性皮炎婴儿及其家庭的生活质量。
Postepy Dermatol Alergol. 2020 Feb;37(1):66-72. doi: 10.5114/ada.2020.93385. Epub 2020 Mar 9.
9
Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.了解特应性皮炎的免疫景观：生物制剂和新兴治疗方法的时代。
Exp Dermatol. 2019 Jul;28(7):756-768. doi: 10.1111/exd.13911. Epub 2019 Apr 15.
10
Effectiveness and safety of combination treatment of herbal medicines and oral antihistamines for atopic dermatitis: a retrospective chart review.草药与口服抗组胺药联合治疗特应性皮炎的有效性和安全性：一项回顾性病历审查
Integr Med Res. 2017 Mar;6(1):19-25. doi: 10.1016/j.imr.2017.01.002. Epub 2017 Jan 17.
本文引用的文献
1
What are the best outcome measurements for atopic eczema? A systematic review.特应性皮炎的最佳疗效指标有哪些？一项系统评价。
J Allergy Clin Immunol. 2007 Dec;120(6):1389-98. doi: 10.1016/j.jaci.2007.08.011. Epub 2007 Oct 1.
2
Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity score.特应性皮炎评分解读的实际问题：SCORAD指数、客观SCORAD及三项严重程度评分
Br J Dermatol. 2007 Oct;157(4):645-8. doi: 10.1111/j.1365-2133.2007.08112.x. Epub 2007 Aug 21.
3
The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective.以患者为导向的湿疹测量方法：从患者角度开发并初步验证一种用于测量特应性皮炎严重程度的新工具。
Arch Dermatol. 2004 Dec;140(12):1513-9. doi: 10.1001/archderm.140.12.1513.
4
Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring?在随机对照临床试验中测量特应性皮炎的严重程度：我们究竟在测量什么？
J Invest Dermatol. 2003 Jun;120(6):932-41. doi: 10.1046/j.1523-1747.2003.12251.x.
5
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group.湿疹面积及严重程度指数（EASI）：特应性皮炎中的可靠性评估。EASI评估者小组。
Exp Dermatol. 2001 Feb;10(1):11-8. doi: 10.1034/j.1600-0625.2001.100102.x.
6
Giving "scale" new meaning in dermatology: measurement matters.
Arch Dermatol. 2000 Jun;136(6):788-90. doi: 10.1001/archderm.136.6.788.
7
Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies.特应性皮炎严重程度评分：三项严重程度评分作为日常实践的粗略系统以及研究的预筛查工具。
Acta Derm Venereol. 1999 Sep;79(5):356-9. doi: 10.1080/000155599750010256.
8
Measurement of body surface area involvement in atopic eczema: an impossible task?特应性皮炎累及体表面积的测量：一项不可能完成的任务？
Br J Dermatol. 1999 Jan;140(1):109-11. doi: 10.1046/j.1365-2133.1999.02617.x.
9
Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis.SCORAD指数的临床验证与指南：欧洲特应性皮炎工作组共识报告
Dermatology. 1997;195(1):10-9. doi: 10.1159/000245677.
10
Measurement of disease activity and outcome in atopic dermatitis.特应性皮炎疾病活动度及转归的测量
Br J Dermatol. 1996 Oct;135(4):509-15.
Zotero 插件